PHAT Phathom Earnings per share trend in current year

Corporate emblem and logo of Phathom (PHAT)

Despite patent conflicts and pressure from insurers, Phathom Pharmaceuticals (PHAT) is maintaining its position. The annual earnings per share growth rate reflects the market consensus on yield rates, where 75.70 represents the current metric. Effective gastritis medications are strengthening the company's pricing power, while physician confidence in innovative esophagitis treatments confirms its status as a leader in the GI sector.

PHAT (Phathom Pharmaceuticals, Inc.) Earnings growth in current year history from 07/04/2022 to 11/14/2026

Financial and market metric breakdowns for Phathom Pharmaceuticals, Inc. (PHAT)

- share price and expert price forecast:
Price Phathom|PHAT - Price Target Chart
- market capitalization data:
Market Valuation Phathom Pharmaceuticals|PHAT - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Phathom Pharmaceuticals|PHAT - Book Capitalization|Market Capitalization to Book Value Ratio phathompharma.com|PHAT - Cumulative Company Assets
- debt burden and liquidity indicators:
Aggregate Debt to Capital Phathom Pharmaceuticals|PHAT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Phathom Pharma|PHAT - Company Debts|Debts to Book Value Phathom Pharmaceuticals, Inc.|PHAT - Company Long-Term Debt|Company Current Liabilities Phathom Pharmaceuticals|Intermediate Coverage Ratio phathompharma.com
- net income and valuation multiples indicators:
PHAT - Company Net Income|Forward Earnings Phathom Pharmaceuticals|PHAT - P/E Multiple|Future Price to Earnings Multiple Phathom Pharmaceuticals|PHAT - PEG Multiple|EV/EBITDA Multiple Phathom Pharmaceuticals, Inc.|PHAT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Phathom Pharmaceuticals|PHAT - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months phathompharma.com|PHAT - Earnings growth in current year|Earnings growth forecast for next year Phathom Pharmaceuticals
- sales volume and revenue information:
PHAT - Revenue and Sales Volume|Company Future Sales Volume Phathom Corp|PHAT - P/S Multiple|Market Cap to Future Revenue Ratio Phathom Pharma
Basic company analysis:PHAT Phathom
Flagship merchandise of phathompharma.com

Phathom Pharmaceuticals' specialization in gastrointestinal drugs and the implementation of eco-friendly waste disposal standards require significant capital expenditures that impact net income. By analyzing EPS dynamics compared to the previous year, an investor assesses the percentage change in earnings per share, which reveals the actual business efficiency and determines whether the securities are overvalued relative to competitors.

Main competitors

TERN: Net earnings per one share growth for the current year|IRWD (Ironwood Pharmaceuticals, Inc.) - Earnings growth in current year|Net earnings per share growth this year Curanex Pharmaceuticals (CURX)|Earnings per share growth in current year Immuron Ltd (IMRN)|Earnings per share growth in current year EVOK (Evoke Pharma Inc.)|Entero Therapeutics - Net earnings per share growth this year|RDHL: Earnings per share growth this year|Palisade Bio Inc. - Earnings growth in current year|JAGX - Earnings growth in current year|BIOR: Earnings growth in current year|Morphic - Earnings per share increase in current year